Bioinformatics, Cardiovascular, Cell Biology, Computational Biology, Kidney, Neurobiology, Systems Biology
Bioinformatics, Cardiovascular, Cell Biology, Computational Biology, Kidney, Neurobiology, Systems Biology
Research
New topic
Dr. Hansen’s research focuses on the cell biology of multiple diseases and developmental changes.
He has built the Molecular Biology of the Cell Ontology, a strictly cell biological ontology, that he uses to identify relevant subcellular processes (www.mbc-ontology.org).
His research approaches employ dynamic models of pathway activities to identify how such subcellular processes interact with each other to generate a whole cell response. He developed a novel drug repurposing approach that counter-regulates disease-relevant pathway activities, independently of the genes involved. Dr. Hansen uses graph theoretical methods to relate differentially expressed genes and other experimental data to prior knowledge. His research topics include neurite outgrowth, aortic aneurysm development and progression, kidney physiology and pathophysiology as well as drug-induced cardiomyopathies.
For more information please jhansenlab.org.
Honors & Awards
2008
Best medical dissertation award
Georg-August-University Göttingen, Faculty of Medicine, Germany
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Hansen has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Hansen has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.